Share on StockTwits

Stock analysts at Stifel Nicolaus reduced their target price on shares of Ocera Therapeutics (NASDAQ:OCRX) from $19.00 to $17.00 in a report issued on Tuesday. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective points to a potential upside of 194.37% from the stock’s previous close.

Separately, analysts at JMP Securities initiated coverage on shares of Ocera Therapeutics in a research note on Wednesday, June 11th. They set an “outperform” rating and a $15.00 price target on the stock.

Ocera Therapeutics (NASDAQ:OCRX) opened at 5.775 on Tuesday. Ocera Therapeutics has a 52-week low of $5.26 and a 52-week high of $19.94. The stock’s 50-day moving average is $6.28 and its 200-day moving average is $9.54. The company’s market cap is $89.7 million.

Ocera Therapeutics (NASDAQ:OCRX) last released its earnings data on Monday, August 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.01. Analysts expect that Ocera Therapeutics will post $-1.88 EPS for the current fiscal year.

Ocera Therapeutics, Inc, formerly Tranzyme, Inc, is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing mechanism-based therapeutics for the treatment of upper gastrointestinal (NASDAQ:OCRX) motility disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.